Average change at 80 weeks Discontinuation rate Three receptorsbut not three identical switches Retatrutide is a single molecule designed to activate GIP, GLP-1 and glucagon receptors
Side effects do not automatically require stopping treatment
Market Opportunities Biosimilar Liraglutide Access Markets, Emerging Geography Expansion, and Precision Obesity Medicine Unlock Underserved GLP-1 Market Growth Segments Biosimilar liraglutide entry represents the first generic competition wave for the GLP-1 weight loss drug category, expanding access for the 480 million obesity patients in lower-middle income countries for whom USD 1,000-plus monthly branded drug pricing is permanently inaccessible
While a single dose of expired medication is unlikely to significantly impact weight loss progress, consistent use of degraded product could result in inadequate appetite suppression and failure to achieve weight management goals
Medically Reviewed by a UK Superintendent Pharmacist This content has been medically reviewed by Mohammed Ismail Lakhi (GPhC: 2072815) , Superintendent Pharmacist at The Care Pharmacy